| Product Code: ETC7743466 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Neurodegenerative Disease Treatment Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Neurodegenerative Disease Treatment Market - Industry Life Cycle |
3.4 Japan Neurodegenerative Disease Treatment Market - Porter's Five Forces |
3.5 Japan Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Japan Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Drug Type:, 2021 & 2031F |
3.7 Japan Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Route of Administration:, 2021 & 2031F |
3.8 Japan Neurodegenerative Disease Treatment Market Revenues & Volume Share, By Distribution Channel:, 2021 & 2031F |
4 Japan Neurodegenerative Disease Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurodegenerative diseases in Japan |
4.2.2 Growing aging population leading to higher demand for treatment |
4.2.3 Technological advancements in the field of neurodegenerative disease treatment |
4.3 Market Restraints |
4.3.1 High treatment costs impacting accessibility for patients |
4.3.2 Stringent regulatory requirements for approval of new treatments |
4.3.3 Limited availability of skilled healthcare professionals specializing in neurodegenerative diseases |
5 Japan Neurodegenerative Disease Treatment Market Trends |
6 Japan Neurodegenerative Disease Treatment Market, By Types |
6.1 Japan Neurodegenerative Disease Treatment Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.1.4 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Parkinsons Disease, 2021- 2031F |
6.1.5 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Alzheimers Disease, 2021- 2031F |
6.1.6 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Spinal Muscular Atrophy (SMA), 2021- 2031F |
6.1.7 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Huntingtons Disease, 2021- 2031F |
6.1.8 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Japan Neurodegenerative Disease Treatment Market, By Drug Type: |
6.2.1 Overview and Analysis |
6.2.2 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By N-methyl-D-aspartate Receptor Antagonists, 2021- 2031F |
6.2.3 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Selective Serotonin Reuptake Inhibitors, 2021- 2031F |
6.2.4 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Dopamine Inhibitors, 2021- 2031F |
6.2.5 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Japan Neurodegenerative Disease Treatment Market, By Route of Administration: |
6.3.1 Overview and Analysis |
6.3.2 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Injectable, 2021- 2031F |
6.3.4 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Japan Neurodegenerative Disease Treatment Market, By Distribution Channel: |
6.4.1 Overview and Analysis |
6.4.2 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.4.3 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
6.4.4 Japan Neurodegenerative Disease Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Japan Neurodegenerative Disease Treatment Market Import-Export Trade Statistics |
7.1 Japan Neurodegenerative Disease Treatment Market Export to Major Countries |
7.2 Japan Neurodegenerative Disease Treatment Market Imports from Major Countries |
8 Japan Neurodegenerative Disease Treatment Market Key Performance Indicators |
8.1 Average time to diagnosis of neurodegenerative diseases in Japan |
8.2 Number of clinical trials for new treatments conducted in Japan |
8.3 Adoption rate of innovative treatment technologies in neurodegenerative disease management |
8.4 Patient-reported outcomes and quality of life improvements post-treatment |
8.5 Rate of hospital readmissions for neurodegenerative disease patients |
9 Japan Neurodegenerative Disease Treatment Market - Opportunity Assessment |
9.1 Japan Neurodegenerative Disease Treatment Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Japan Neurodegenerative Disease Treatment Market Opportunity Assessment, By Drug Type:, 2021 & 2031F |
9.3 Japan Neurodegenerative Disease Treatment Market Opportunity Assessment, By Route of Administration:, 2021 & 2031F |
9.4 Japan Neurodegenerative Disease Treatment Market Opportunity Assessment, By Distribution Channel:, 2021 & 2031F |
10 Japan Neurodegenerative Disease Treatment Market - Competitive Landscape |
10.1 Japan Neurodegenerative Disease Treatment Market Revenue Share, By Companies, 2024 |
10.2 Japan Neurodegenerative Disease Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here